Who are the key players in Global Biosimilars Treatment Market industry?

The top five key players in the Global Biosimilars Treatment Market include Pfizer Inc., Novartis AG (Sandoz), Amgen Inc., Samsung Bioepis, and Biocon Limited. These companies lead the market through extensive R&D, robust biosimilar pipelines, strategic collaborations, and global commercialization, establishing a strong presence in multiple therapeutic areas.

What is the Global Biosimilars Treatment Market growth?

The Global Biosimilars Treatment Market is experiencing rapid growth, with a CAGR of over 20% in recent years. In 2023, Sandoz (Novartis AG) saw significant revenue increases due to market expansions and new biosimilar launches, driven by patent expirations and increasing demand for cost-effective biologic alternatives.

Which segment accounted for the largest Global Biosimilars Treatment Market share?

The oncology segment accounted for the largest market share in the Global Biosimilars Treatment Market. This is due to the high prevalence of cancer, rising adoption of biosimilar monoclonal antibodies, and the launch of new biosimilars targeting blockbuster oncology biologics, providing accessible and affordable cancer treatments globally.

What are the factors driving the Global Biosimilars Treatment Market?

Key factors driving market growth include rising incidences of chronic diseases, increasing healthcare cost pressures, and regulatory support for biosimilar approvals. For example, Amgen Inc. has rapidly expanded its biosimilar portfolio to address the growing demand for affordable biologics in autoimmune and oncology indications.

Which type accounted for the largest Global Biosimilars Treatment Market share?

Monoclonal antibodies accounted for the largest type share in the Global Biosimilars Treatment Market. Their widespread use in treating cancers, autoimmune, and inflammatory conditions, along with numerous monoclonal antibody biosimilar approvals and launches, has driven significant market uptake and penetration globally.

Home Healthcare

Global Biosimilars Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: Global Biosimilars Treatment Market
Brand: Bussiness Insights

Global Biosimilars Treatment Market: by Type (Monoclonal Antibodies, Recombinant Hormones, Fusion Proteins, Immunomodulators, Insulins, Erythropoietin), Application (Oncology, Autoimmune Diseases, Chronic Diseases, Blood Disorders, Infectious Diseases, Other Applications), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Drug Stores, Others), Technology (Recombinant DNA Technology, Monoclonal Antibody Technology, Genomics, Proteomics, Bioengineering, Others), Organization Size (Small, Medium, Large) and By Global â Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 21-04-2026 | Format: PDF | Report ID:21961 | Author: Lily

RD TOC Segmentation Research Methodology Request For Free Sample Copy

Global Biosimilars Treatment Market, 2025-2035

The global biosimilars treatment market is characterized by robust growth, driven by increasing adoption of cost-effective biologic therapies and patent expirations of blockbuster drugs. Biosimilars, developed as highly similar alternatives to original biologic medicines, offer comparable safety, efficacy, and quality, presenting a valuable solution for healthcare systems managing chronic and life-threatening diseases. This comprehensive evaluation covers market segmentation by type, application, technology, distribution channel, and organization size, alongside regional and company landscape from 2020 to 2035.

Latest Market Dynamics

Key Drivers

Patent expirations of major biologic drugs have created significant opportunities for biosimilar manufacturers, spurring rapid market entry and competition. In 2024, Amgen launched a biosimilar for Humira in the US, exemplifying this trend.

Escalating demand for cost-effective treatments in chronic diseases such as cancer and diabetes is driving biosimilar uptake. Biocon reported a surge in biosimilar revenue in early 2024, reflecting growing healthcare provider and patient acceptance.

Strategic collaborations between biotech firms and pharmaceutical giants to accelerate biosimilar pipelines. For instance, Samsung Bioepis and Organon broadened their biosimilar portfolio with new approvals in 2024.
Increased regulatory approvals across major markets, with EU and FDA expediting review processes for biosimilars as of 2024, fostering competition and faster product availability.

Key Opportunities

Expanding market access in emerging economies, where healthcare systems seek affordable biologic therapies. Biocon has rapidly scaled operations in Southeast Asia and Latin America in 2024.
Digital transformation in biosimilar supply chains and e-pharmacies enables wider distribution and patient outreach, as seen with Sandoz partnering with major online platforms in 2024.

Market acceptance barriers among clinicians and patients remain, with ongoing education needed on biosimilar equivalence. Pfizer has initiated global campaigns to address these in 2024.
Complex and evolving regulatory requirements across geographies increase development timelines and costs, affecting companies like Teva Pharmaceutical in 2024.

Intellectual property litigation is a persistent challenge, delaying launch timelines. Novartis encountered biosimilar launch delays in the US due to patent disputes in 2024.
Manufacturing complexity and stringent comparability requirements escalate production costs, limiting the entry of smaller players. Mylan faced increased COGS during new biosimilar launches in early 2024.

Global Biosimilars Treatment Market Share (%), By Type, 2025

To learn more about this report,Download Free Sample Report

Monoclonal antibodies dominate the biosimilars market due to their extensive use in oncology, autoimmune, and other chronic diseases. Recombinant hormones and insulins are also significant, addressing endocrine and metabolic disorders. The market landscape in 2025 sees monoclonal antibodies at the forefront, driven by multiple product launches, while recombinant hormones and fusion proteins also hold notable shares. This composition reflects the broadening therapeutic applications and increasing confidence in biosimilars across major disease areas.

Global Biosimilars Treatment Market Share (%), By Application, 2025

To learn more about this report,Download Free Sample Report

The oncology segment leads the biosimilars treatment market, capturing the largest share in 2025 as biosimilars offer critical cost savings in cancer care. Autoimmune disease treatments follow, facilitated by developed biosimilar portfolios for conditions like rheumatoid arthritis. Chronic diseases, blood disorders, and infectious diseases represent growing applications, signaling biosimilars’ expanding impact in various therapeutic realms.

Global Biosimilars Treatment Market Revenue (USD Million), 2020-2035

To learn more about this report,Download Free Sample Report

The global biosimilars treatment market is forecast to grow from 17,550 Million in 2020 to 65,900 Million by 2035. Revenue growth is propelled by patent expirations, increased chronic disease burden, and accelerated regulatory approvals. The period between 2025 and 2030 is marked by steeper growth as new biosimilar entrants and expanded indications fuel adoption. By 2035, the market is expected to reach unprecedented levels due to wider global access and technological advancements.

Global Biosimilars Treatment Market YOY Growth (%), 2020-2035

To learn more about this report,Download Free Sample Report

Year-over-year growth rates for the global biosimilars treatment market peak in the years following key biosimilar drug exclusivities and major regulatory approvals. A strong surge from 2024 to 2027 is observed, with YOY growth stabilizing at high single digits by 2030 as the market matures and becomes more competitive, reflecting the sector’s promising outlook.

Global Biosimilars Treatment Market Share (%), By Region, 2025

To learn more about this report,Download Free Sample Report

Europe leads the global biosimilars treatment market in 2025 due to supportive regulatory environments and high biosimilar uptake. North America holds the second-largest share as more biosimilars enter the US market post-patent expiry. APAC continues to expand rapidly, driven by increased healthcare access and lower-cost production. Latin America, MEA, and Africa are emerging regions with growing biosimilar adoption.

Global Biosimilars Treatment Market Players Share (%), 2025

To learn more about this report,Download Free Sample Report

The global biosimilars market is fragmented with top players holding substantial, yet competitive shares. Pfizer leads the market in 2025, followed by Novartis (Sandoz) and Amgen, which have robust portfolios and global reach. Biocon, Celltrion, and Samsung Bioepis are major contributors, reflecting the mix of established pharma and specialized biotechs in driving innovation and access.

Global Biosimilars Treatment Market Buyers Share (%), 2025

To learn more about this report,Download Free Sample Report

Hospital pharmacies are the primary buyers of biosimilars, accounting for the largest share in 2025 due to institutional procurement for major chronic and acute care needs. Retail pharmacies are gaining traction as biosimilars enter outpatient settings, while online pharmacies increasingly play a role in distribution, reflecting changing healthcare delivery trends.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	30600
Regions	North America, Europe, APAC, Latin America, Middle East & Africa
Segments	Monoclonal Antibodies, Recombinant Hormones, Fusion Proteins, Immunomodulators, Insulins, Erythropoietin, Oncology, Autoimmune Diseases, Chronic Diseases, Blood Disorders, Infectious Diseases, Other Applications
Players	Pfizer Inc., Novartis AG, Amgen Inc., Biocon Limited, Celltrion Healthcare, Samsung Bioepis, Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Merck & Co., Inc., Sandoz International GmbH, Hospira, Inc., Dr. Reddy's Laboratories, Boehringer Ingelheim, Biogen Inc.

Key Recent Developments

June 2024: Amgen launched Amjevita, a biosimilar to Humira, in the US, expanding its biosimilars portfolio.
July 2024: Sandoz received FDA approval for a biosimilar pegfilgrastim, strengthening its leading position in the US biosimilars market.
August 2024: Biocon received marketing authorization for insulin glargine in the European Union, furthering its EU expansion.
September 2024: Pfizer announced a global awareness initiative to support biosimilar adoption among healthcare professionals.
October 2024: Celltrion Healthcare signed a cross-border distribution agreement with a Latin American healthcare group to boost biosimilar access.

Frequently Asked Questions

About the Author

Lily

Senior Market Research Analyst

Lily is a Senior Market Research Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Lily brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Lily has helped organizations translate data into actionable growth strategies.

HealthcareMarket ResearchIndustry AnalysisStrategic Consulting

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Download Sample

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

Speak to Analyst

Global Biosimilars Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Global Biosimilars Treatment Market, 2025-2035

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

Global Biosimilars Treatment Market Share (%), By Type, 2025

Global Biosimilars Treatment Market Share (%), By Application, 2025

Global Biosimilars Treatment Market Revenue (USD Million), 2020-2035

Global Biosimilars Treatment Market YOY Growth (%), 2020-2035

Global Biosimilars Treatment Market Share (%), By Region, 2025

Global Biosimilars Treatment Market Players Share (%), 2025

Global Biosimilars Treatment Market Buyers Share (%), 2025

Study Coverage

Key Recent Developments

Frequently Asked Questions

About the Author

Related Reports